of of across achieved a highlight in our quarter the and program, number in Thanks, I’ll a Stan. We studies. overall these second clinical few of the milestones the context
X, Slide to switch maybe please. So
Here we are.
preliminary programs clinical HIV and group efficacy in touch the immunogenicity six-month our our the and dose influenza U.S. the efficacy data Moved study and study the we is based safety, collected the in X ongoing well Phase on that’s is well a safety evaluation, data study about included a safety of study X, this that are big licensure-enabling I’ll efficacy as exploring a small U.S., Africa Australia, population. there well. a the as as this UK and of the immunologic define a defining which to And I’ll study on U.S. X that off Phase safety and subjects. the in conducted data to profile efficacy study we’ve overall we and as the preliminary and Moved and some and here safety established as study well bit talk Phase our start South the beginning profile profile in we later. X as data co-administration the of licensure-enabling conducted that the as the data boosting, development, in finally, since level, this the over X we’ve Phase Phase small later on conducted So in the large the in first
Let’s please. X, to move on Slide
adults Here’s you people study is what ahead in the And was XX,XXX cross to And over crossover remind that Mexico. fashion. blinded included and complete. two dose know, these XX age. we’ve this you gone greater to one. randomized crossover a two years as the the in the design almost of is and And of And U.S. enrollment in than the of PREVENT-XX aged study it
The age, of these is this the study for and immunogenicity XX include dosing file safety, children. adolescents we is years to expanded ongoing. we X,XXX enrolled complete and and to XX Additionally, of efficacy
we that next plan crossover blinded be a have beginning should week. and We
X, Slide to on move please. let’s So
Here for remember, primary as as was things. From overall, endpoint. of see what the other as you can the efficacy Kaplan-Meier the Stan curve overall the efficacy I’ve X% And displayed mentioned. couple graph, you a
rates began and the placebo see vaccine was of dose second the before the separation can You before XX day given.
convergence occurred no group. vaccine. the through Additionally, right And I the there’s placebo remind for you that can cases severe of you see the protection suggesting all in want durability of day-XX, to finally, our
from move the X. updated Slide the is got chatted which data, additional to we last. on sequence let’s And Slide disease So in cases contains because X study. we this from is data
way slide neither the is interest in concern variants are concern that green. yellow this and represented are of are variants red. the represent the strain of Wuhan are that matched designed that the of like is variants to strains those closest So in in more interest The or strains the
can remind placebo XX in in one You a to two had we cases the vaccine the And was the cases this see XX study. overall group. you, randomized group and
would we talked like consider group lower So of placebo can in efficacy half a was bound with the been normally a that we X% have what you about study. And randomized XX%. of one-to-one
against there we key strains of Wuhan was were a Our or endpoint secondary XXX% concern, and interest strain of most efficacy. areas those areas had that like neither
irrespective efficacy or can You a arm. I vaccine in of strains XX non-variants. moderate had that’s no disease causing and disease green with severe under are variants a lower bound we guess, the of XXX% and see there
analysis saw is a of in in study XX%. column. the all end XX% lower consistency concern with no then against finally, the we all You of precision variants against the in high the and And can disease had XX%. we first UK. variant to seen cases point at as points efficacy of the which vaccine enough efficacy with there see also group of were or interest, of estimate exploratory this under which bound We we had vaccine lower patients the of XX.X% of a these the B-XXX as estimate really bound is And bound. had across of alpha What’s lower efficacy well remarkable the moderate
has a outlines the randomized and all design X. is the Slide we with crossover one-to-one greater study. enrollment XX of XX,XXX to the turn is study also than vaccinations age. subjects let’s years X of So these adults This cross Slide completed. this And of over been UK
Kaplan-Meier now denotes and of endpoint, can again separation convergence the there’s XX% all we’ve again, small X, red Once durability disease which And let’s no before. primary previously Slide once overall. efficacy the was right shows day protection. at placebo axis suggesting talked about the beginning curve move a group. published primary severe it’s and to the curve So see of XX that on of curves you the in the There’s they’re or as
to we fact, our see the In yet group. severe in all programs, vaccinated a case over of have
people I’ll with sub licensed that was What a events both can reactogenicity favorable. the local first is Novavax hand systemic a symptoms, slide. you and with and alone, but to tolerable. co-administration is highlighted Part data is I study, is flu dose the efficacy efficacy There’s that of I’ve preserved seroconversion influenza in the as vaccine the XX.X%. The even Let’s side what profile saw we did at subsequent were turn study placebo a was when this remind XX. that Slide of quite was here And of systemic was flu. of increase only you mild is this received XXX and preserved and And of well. amount And this dose vaccine a overall, in the small local subgroup the a reactogenicity see the a analysis mimicked in of study it And XXXX. XX.X%, the detail influenza flu individuals. left and combination vaccine side alone, HAI the of study of though influenza a in the of we small overall a very the then subgroup those was where
look it let’s XX So and to immuno. at go Slide
people were So of received when who age, vaccine, with vaccine. responses who hand The vaccine And was years what’s the side, And the and health on panel. is plus displayed compared we given to because works very influenza alone well. data. licensed see by cell subjects small And people Slide older older who can UK the UK standards XX adjuvanted XXXX. group only XX XX you in they’re subjects on the of the received very vaccine of culture quadrivalent had to the hand This left HAI is infrastructure aged the this public received the in received a our subjects right influenza. who XX quadrivalent
wide. quite are intervals conference the So
a However, were larger of on the left individuals. hand group side, these
all flu we precise can be were of responses And for the immune in vaccine. to our the more can see strains. four preserved So vaccine response you the flu that to estimates HAI the
the the co-administrator fact, seroconversion the numerically in compared as to were as vaccine responses, vaccine HAI alone. responses the well In higher
in Slide is This of please. So powered. the on efficacy results let’s next comparison two our slide, Phase conducted the studies from X XX, independently that move to a were
matched interest. than can study, the strain the efficacy remarkably those studies see two the the saw efficacy and XX% was efficacy the the XX% point Against in that Against interest vaccines indicating concern less a alpha, in U.S. UK, against variants were in percentage against saw concern that of the and in that and is very single study, greater UK XX% alpha, the where U.S. XXX% response XX% XX%, non-variants the UK U.S., of consistent, was overall we in we prototype You guess, a in in U.S. or against difference Mexico, or had spreading, and in a against barrier XX%. I the efficacy we robust. a variants
cases UK have to say this in placebo our vaccine finally, well estimate cases the all in variants we quite were a that would the South also placebo and disease but And efficacy gain the have didn’t were this cases in severe severe works all severe efficacy, U.S. So the We observation well. fact. And in hospitalized in group. against Africa, group the enough as was in I XXX%.
make design want boost the of of South and received on people different move a Africa two six So two in design. Phase the is the that please. XX the bit a enrollment to is got I the from at let’s XX, has to display crossover Xb all And is point months. Slide here this only placebo who And doses little of vaccine the that started. other initially Slide vaccinations
people from population. a months, this and However, will initially allow doses and immunogenicity boost this got at both boost single who collect to safety dose got additional perspective two data six a us in the
started So Slide Australia let’s move our that Phase of study U.S. XX to the ago. in displays over design we Slide year XX, a and Xb please. the study
went dose XX at aged age. and Here series, of year. two we months. we XX select individuals adults plan of They X initially enrolled We XXXX. of in half greater microgram were the who those them two boosted groups zero who boost are on these and we were back of some adults And talking primary half the the were that an have at These the group six X,XXX to additional XX After XX than XXX years I’ve day No. at highlighted in are highlighted dose in doses slides red the of we’ll people a red printed please. perhaps about. click boosted at be and receive with one
XX, Slide to please. go Let’s
And discontinuations, medical Slide dose events events, displayed adverse And adverse rates we’ve XX to medically can a SAEs you in are see And three. overall there dose events consistency events adverse severe two And adverse severe indeed. low SAEs, there’s So between excess and of the attended dose dose displays to adverse dose and potentially of one, events, and lot an three. mediated of one isn’t complications. the three. two comparing AEs very immune
suggest data monitoring this concerns and So was reviewed safety by and with they committee, our external no a we proceed that vaccination. voiced
or we XX, Let’s an for reactogenicity for expected And then after What local reactions which which events median highlights local low median Grade of you you move less days X what more of reactions, days. additionally, is dose the exception a can of for to see was systemic duration two vaccination. Slide is vaccinations. the two than than mild with with reactions were moderate please. Slide was or that additional had either of dose short also see the erythema, XX% can three, very and increase with X.X is XX rate more the none, completely or
Slide to go to Slide XX, and saw which details companion similar is please. slide, a the it’s XX previously. very systemic what Let’s we symptoms
XX% than is muscle or rate exception with fatigue, again event increased Once days. with low As symptoms plus one the quite with and And more the reported short the exception in was with of pain, two the symptoms. moderate median mild none, which overall. dosing, – day of duration expected either was
data. response the with detailed conducted XX immunokinetics the is here And and our prototype. assay. immune against at Let’s is this some anti-IgG the Slide I’ve move of validated What response, immuno look to
can is doses and boosting. it the you This from here impact after over increased over by it’s X.X it, XX, to peak a So And see which XXX,XXX adults up both two vaccination. XX,XXX, represents Slide day time had we point And units. the adults, primary decreased peak response when the in seen older to the on this the is fold XX that same good boosted was a after data, compared but please. age. rose the displayed younger we
younger fact, have was likely the with. because than even In higher lower older begin boost, the adults slightly adults is titers to impact they to which to
XX, Let’s move on to Slide please.
I’ve all until was shown up anti-spike data strain. you for the So emergency from now the perspective our validated prototype an against
to you We well. is first also XXX,XXX can a developed And a six in a for assay validated got boost XXX. Day South anti-spike X,XXX at month with one that we see, as the at period time really Africa. variant, so Beta From over day nice the the IgG almost identified
have a against know against variants. some evidence variants. we potential is good have efficacy is We to this true, has what here we vaccine that So the because cross-react
go at again, Let’s and the wild with fold similar rise you and an against peak to type IgG Once month what at six, please. maybe XX, XX, can displays Slide responses Slide saw in Day with the XX neutralization. this patterns it boost older is at see increase X,XXX we the prototype adults. very over strain,
Let’s to move on Slide XX.
to showed. this on the the peak I’ve is middle what observed have we that boost UK column PREVENT-XX. data side, responses we Phase in we right hand And in displayed responses the So study that in observed finally, I slide, on immune in the that the the the X next is
durability that hope against had only to us well overall. rise. as a fold studies. increase we Additionally, non-variants, two compared vaccine you we that a of also protection not programs, efficacy, is see in the as X.X to where showed I’ve we’re gives but going what X.X of high against efficacy is the And of protection top variants, the Phase X to put the lot can X Phase This
And This the shows is companion to slide. well slide micro can U.S. you peak program. here. had responses. as neutralization X study. the Let’s we these the of next slide, a guess, boost wild with the then point our things move in a on couple from Phase Phase see out once as I X a – in type large And our UK, but responses again, to
fold immune were micro we is for maturation our for such And We efficacy is neutralization also spread have we the suggests understand potential this of greater data the the bit to One of greater and to them a this the that – of response response saw curious variants. with the in vaccine, IgG. good about to vaccines to more this because slides. couple next quite against these immune rise
move to XX Let’s XX. is Slide Slide slide. pretty a complicated
functional So a I’m assay. going this my through inhibition time going We developed human to take ACEX data.
we Alpha. show Delta, do vaccination spike the in And and from this are do block strain, is that did interaction. what So proteins we we Beta is developed prototype assay generated antibodies the we by that that can what
a is assay. it functional So
the hand the you Day On side, left see XX can data.
you the you and want in So response the red see the is I doses, you variants Beta, Delta, XX% can Alpha. peak after was responses green against prototype, see XX and that XX% between the and was functional efficacy data the prototype displayed Day and And two can blue remind then black, And two. – to other the those against between and displayed immune between Alpha XXX%. XX%. immune and And
for for we between we efficacy saw high you the that, that that So will against hope Alpha. have saw variants which be those the prototype somewhere
had you a hand between saw to boosts the increase Day side, over And thing. XX. six-fold responses see XX.X can what On the we fold we at right after
Importantly, lot attention. Delta is getting of a
after the couple that of the X.X that rise had no is behind. one on You series. other primary part them observations it of response graph, And a can over the of we see left one peak vaccination fold this
especially graph. the protective be those the high of the people XXX% the we’ve to boosted left compared here of shown seen into that see can hand were which were You levels when you levels, to on side
we maturation the immune three really And Another observation of very to attribute the have responses is across consistent boosting. response that we really with this, the variants.
XX, Slide is So on summary. to which let quick me a move clinical
and of both study. interest levels have the have variants Alpha UK independent well against as from two efficacy, of have the showed over these against in B.X.X.X high efficacy studies we variants, shown And studies X in variant, that vaccine U.S. XX%. of and as So the concern data both all U.S. strong XX.X% Phase the overall
data vaccination adversely a this neutralization with the this I’ve with we dose slide, single in primary not with Next Alpha, against X.X.X.X Delta, we of series, between after are our boosting functional our well increase. shared that also boosted our the to the peak wild the we that immune take X.X our X.X glue, only about boosting as to And use immune type fold it ACEX from able of increases responses, were Beta boosted these think significantly impact to fold this coordinate anti-spike share We In vaccination primary went doesn’t vaccine but and XX.X influenza today response. six you and at but data you response, as over support and IgG campaign. response. months, a inspiration it in will furthermore, immune peak
boosting So our be the have vaccine campaign. of into high annual nation hopes incorporated that we influence could
turn So over let Stan. this me back to
